GI Motility Agents Do Not Need Dedicated CV Safety Studies, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Gastrointestinal Drugs Advisory Committee overwhelmingly opposes CV-specific studies for the class of 5-HT4 receptor agonists, but says Phase III trials should include patients at high risk for events.
You may also be interested in...
CV Safety Requirements For Motility Drugs Could Take Indication-Centric Approach
At a Nov. 17 meeting on 5-HT4 receptor agonists, FDA will ask advisory committee members whether an increased cardiovascular risk would be acceptable depending upon the context of use and whether sponsors need to conduct a dedicated CV study either before or after approval.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.